Similarly, no association was found between gp100 intensity and clinical or pathological characteristics (depth, ulceration, mitoses, gender or age among primary melanomas and BRAF status, gender or age within the metastatic disease cohort). This evidence concerns the gene PMEL and metastatic neoplasm.